SCHEMBL19243152

SCHEMBL19243152

O=C/C(=C(\Br)c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
MAPK1 P28482 2/20 0.48
CA2 P00918 3/20 0.39
PTPN1 P18031 2/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
TSHR P16473 4/20 0.39
CES1 P23141 3/20 0.39
CES2 O00748 2/20 0.39
DAO P14920 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
AKR1C1 Q04828 1/20 0.38
AKT1 P31749 1/20 0.37
GSK3B P49841 1/20 0.37
CYP3A4 P08684 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9615018 0.83 ALDH1A1 (0.59) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL9615016 0.83 ALDH1A1 (0.59) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL1053736 0.81 CES1 (0.48) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL8104960 0.81 CES1 (0.48) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL8104955 0.81 CES1 (0.48) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL9115772 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL9115759 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL19243244 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL19209092 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1CA2PTPN1
SCHEMBL19209090 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1CA2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER IDO1, IDO2, TDO2 ALDH1A1 946/4885TDP1 374/4885MAPK1 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.